Efficacy and safety of ruxolitinib in intermediate‐1 IPSS risk myelofibrosis patients: Results from an independent study

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1069|36|1|285-290

ISSN： 0278-0232

Source： Hematological Oncology (Electronic), Vol.36, Iss.1, 2018-02, pp. : 285-290

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Real-life Safety and Efficacy of Vardenafil: an International Post-marketing Surveillance Study – Results from 29 358 German Patients

By van Ahlen H   Zumbé J   Stauch K   Landen H  

The Journal of International Medical Research, Vol. 33, Iss. 3, 2005-05 ,pp. : 337-348

Field House Publishing

Access to resources Recommend Favorite

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis

By Vaddi Kris   Sarlis Nicholas J   Gupta Vikas  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 16, 2012-11 ,pp. : 2397-2407

Informa Healthcare

Access to resources Recommend Favorite

Ruxolitinib: In the Treatment of Myelofibrosis

By Yang Lily P.H.   Keating Gillian M.  

Drugs, Vol. 72, Iss. 16, 2012-11 ,pp. : 2117-2127

Adis International

Access to resources Recommend Favorite

Efficacy and Safety of Donepezil in Patients with Alzheimer’s Disease: Results of a Global, Multinational, Clinical Experience Study

By Boada-Rovira M.  

Drugs & Aging, Vol. 21, Iss. 1, 2004-01 ,pp. : 43-53

Adis International

Access to resources Recommend Favorite

Combination of Amlodipine plus Angiotensin Receptor Blocker or Diuretics in High-Risk Hypertensive Patients: A 96-Week Efficacy and Safety Study

By Liyuan  

American Journal of Cardiovascular Drugs, Vol. 12, Iss. 2, 2012-04 ,pp. : 137-142

Adis International

Access to resources Recommend Favorite